Maryland Psychiatric Research Center (MPRC)

Since 1989, the Treatment Research Program (TRP) has been committed to advancing the understanding and treatment of schizophrenia. Our mission is to improve the lives of individuals living with schizophrenia by conducting innovative research, including clinical trials of new medications and strategies that support recovery.

Challenges in Schizophrenia Treatment

While significant progress has been made in understanding schizophrenia over the past decade, the development of new treatments has lagged. Translating research breakthroughs into effective medications has proven difficult, and many patients still face barriers to achieving optimal outcomes due to the lack of personalized treatment approaches.

Current treatments often do not account for the complex and diverse nature of schizophrenia. Most therapies are developed based on broad diagnostic criteria, which doesn't reflect the individual differences in how the condition manifests. This one-size-fits-all approach leaves many patients without the tailored care they need.

The Need for Personalized Care

Schizophrenia affects people in different ways, and so do its treatments. As a result, successful treatment can be a struggle. At the TRP, we are driven by a commitment to personalized medicine—developing treatments that address the unique needs of each patient, rather than relying on generalized approaches.